Related Experiment Video

Updated: Sep 16, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K

SCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women: This statement was endorsed by the Heart

Suzanne J Baron1, Josephine C Chou2, Tayyab Shah3,4

  • 1Massachusetts General Hospital, Boston, Massachusetts.

Journal of the Society for Cardiovascular Angiography & Interventions
|July 9, 2025
PubMed

Insights

Cardiovascular disease is a leading cause of death in women. Addressing sex-based disparities in cardiogenic shock (CS) treatment is crucial for improving outcomes and advancing women's cardiovascular health.

Area of Science:

  • Cardiology
  • Women's Health
  • Medical Consensus

Background:

  • Cardiovascular disease (CVD) is the primary cause of mortality for women globally.
  • Cardiogenic shock (CS) in women has alarmingly high mortality rates.
  • Existing sex-based disparities in CS treatment delivery negatively impact outcomes for women.

Purpose of the Study:

  • To provide a comprehensive summary of current cardiogenic shock (CS) treatment in women.
  • To identify critical evidence gaps in the diagnosis and treatment of CS in women.
  • To guide clinical practice by addressing sex-based disparities in cardiovascular care.

Main Methods:

  • Consensus statement development.
  • Literature review focusing on sex-based data in CS treatment.
  • Synthesis of current evidence and identification of knowledge gaps.

Main Results:

  • Current literature has limited sex-specific data on cardiogenic shock (CS).
  • Significant disparities exist in the timely administration of optimal CS treatments for women.
  • Evidence gaps hinder the development of tailored best practices for women with CS.

Conclusions:

  • Improving women's cardiovascular health requires addressing sex-based disparities in CS care.
  • Clinicians can use this consensus statement as a resource for managing CS in women.
  • Further research is essential to establish evidence-based guidelines for diagnosing and treating CS in women.

Keywords:
cardiogenic shockmechanical circulatory supportsex differences

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K
Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine05:36

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

Published on: January 30, 2020

7.9K

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
81
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
38
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
73
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
32
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
38
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
61